Nevada Coalition for Psychedelic Medicines

Nevada Coalition for Psychedelic Medicines Saving Lives | Revolutionizing Mental Health The Nevada Coalition for Psychedelic Medicines is dedicated to healing through the use of psychedelic substances.

We strive to increase access to and understanding of these substances as potential therapies for mental health and well-being and to eliminate the stigma and criminalization associated with their use. Through collaboration, advocacy, and education, we aim to improve the health and lives of individuals in our state and nation.

Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to...
04/06/2026

Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to the Senate, with a vote of 137 to 11.

While the bill was originally focused on helping veterans, Republican state Rep. Matthew Overcast pushed to expand the bill to also include first responders.

This bill requires the Missouri Department of Mental Health to provide grants totaling $2 million for the research on alternative therapies, subject to lawmakers approving the appropriation.

The state would collaborate on the study with a Missouri university hospital or medical center operated by the U.S. Department of Veterans Affairs in Missouri. The focus of the treatment is on veterans suffering from post-traumatic stress disorder, depression, substance use disorders, or for those who require end-of-life care.

The su***de rate among veterans in Missouri is nearly double the state rate and one of the highest in the country.



Check out the full article here:
https://www.newstribune.com/news/2026/apr/05/missouri-house-passes-bill-to-study-psilocybin-therapy-for-veterans-first-responders/

Katharine Harris, a fellow in Drug Policy at Rice University’s Baker Institute for Public Policy, said in some ways she ...
04/03/2026

Katharine Harris, a fellow in Drug Policy at Rice University’s Baker Institute for Public Policy, said in some ways she was not surprised that the state could not find a private-sector drug company to partner with on i᥇oᧁainꫀ research.

State lawmakers set several requirements that companies had to meet. They needed to propose a feasible plan to develop i᥇oᧁainꫀ and obtain FDA approval, establish a corporate presence in the state, match the $50 million state investment, and agree to allow the state to receive at least 20% of the future sales of the drug.

“That may have been somewhat of a demanding ask in this research area, which is relatively high risk in terms of both the regulatory environment and also the scientific and medical side of it,” Harris said. “I think it’s not all that surprising that they had some difficulty finding an applicant who met the requirements.”

“It is certainly possible that there were very few that could have met this bar, and maybe those that could have didn’t want to, but we need more information to really be able to understand that decision,” Harris said.

Check out the full article here:
https://www.kvue.com/article/news/local/texas/texas-ibogaine-research-program-unable-drug-company-partner/269-164c7307-f6f0-48eb-b3b4-87d1fa5e7460

I᥇oᧁainꫀ and the Bicameral Mind is the definitive guide to the transformational potential of the world’s most complex ps...
04/01/2026

I᥇oᧁainꫀ and the Bicameral Mind is the definitive guide to the transformational potential of the world’s most complex psꪗchꫀdeꪶic medicine. After years of development, the book is published by Park Street Press and is available to pre-order today.

“Jonathan Dickinson has spent years at the intersection of indigenous wisdom, clinical practice, neuroscience, and human struggle. Through his work in Mexico and his engagement with traditional practitioners in Central and West Africa, he offers a perspective few others possess. His writing is not sensationalized. It is measured, observant, and informed by years of listening-to patients, to healers, to scientists, and to families desperate for answers.” Foreward by: Rick Perry; Chairman of Americans for I᥇oᧁainꫀ and Former Governor of Texas

Whether you’re an Ambio alum reflecting on your own journey, a clinician seeking to understand i᥇oᧁainꫀ’s mechanisms, or if you’re considering or preparing for treatment, this book offers both depth and rigor, balancing science and spirituality. I᥇oᧁainꫀ and the Bicameral Mind offers not only a deeper understanding of this medicine and our relationship with it, but a new framework for engaging with the complexity and therapeutic potential of altered states of consciousness.

Ibogaine and the Bicameral Mind releases September 8, 2026, and pre-orders are available now at jonathandickinson.ca
https://shop.jonathandickinson.ca

Americans for I᥇oᧁainꫀ is a 501(c)(3) nonprofit organization advancing science-based education, clinical research, and r...
04/01/2026

Americans for I᥇oᧁainꫀ is a 501(c)(3) nonprofit organization advancing science-based education, clinical research, and responsible medical access to i᥇oᧁainꫀ therapy for addiction and trauma.

They are an organization dedicated to advancing understanding and responsible medical access to i᥇oᧁainꫀ therapy for individuals struggling with addiction, trauma, and co-occurring mental health conditions.

They bring together clinicians, researchers, veterans, first-responders, policymakers, and advocates united by a shared conviction: that every American deserves access to the most promising evidence-based treatments available—including i᥇oᧁainꫀ.

Founded to address the growing disconnect between emerging i᥇oᧁainꫀ research and U.S. regulatory policy, AFI serves as a credible, nonpartisan bridge between the scientific community, Congress, state legislatures, and the public.

To learn more about the great work being done by AFI, check out their website linked below:
https://www.americansforibogaine.org/about/

Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order ...
03/31/2026

Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order to advance to the Senate. The committee deemed the bill inexpedient to legislate, and when it got to the floor for the second time on Thursday, members overturned that recommendation and then adopted the major change that only contemplates a potential regulated access model instead, with an advisory board tasked with studying the issue. That dialed-back version ultimately passed.

“The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of ps𝒾𝓁𝑜cy𝒷𝒾𝓃 which that same provider has produced for a medical intervention,” the bill, HB 1809, says.



Check out the full article here:
https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/

A phase 2b randomized clinical trial published in JAMA Psychiatry found that inhaled GH001, a synthetic formulation of m...
03/30/2026

A phase 2b randomized clinical trial published in JAMA Psychiatry found that inhaled GH001, a synthetic formulation of mebufotenin (5-ℳ𝑒𝒪-DℳT), produced rapid antidepressant effects in adults with treatment-resistant depression (TRD). 

The trial was conducted at 16 sites in Europe and compared a single-day individualized dosing regimen of GH001 with placebo over a 7-day double-blind period, followed by a 6-month open-label extension. 

The study’s placebo-controlled data showed clinically meaningful symptom improvement within 8 days after a single-day dosing regimen, which is notable in a population with substantial unmet treatment needs. 

Safety will remain central to interpretation. Treatment-emergent adverse events occurred in 72.5% of GH001-treated patients versus 7.3% of placebo-treated patients, but all adverse events in the GH001 group were mild or moderate. The most common events were nausea, salivary hypersecretion, paresthesia, dysgeusia, and headache. No patients discontinued treatment because of adverse events. 

To explore the report, follow the link below:
https://www.hmpgloballearningnetwork.com/site/pcn/news/inhaled-psychedelic-therapy-shows-rapid-trd-relief-phase-2b-trial

Meet: The Psꪗchꫀdeꪶics & Pain Association The Mission of PPA: “Our mission is to reduce pain and improve health with psꪗ...
03/27/2026

Meet: The Psꪗchꫀdeꪶics & Pain Association

The Mission of PPA: “Our mission is to reduce pain and improve health with psꪗchꫀdeꪶic medicines. The Psꪗchꫀdeꪶics & Pain Association (PPA) works to advance research, understanding, awareness and access to psꪗchꫀdeꪶic medicines for the treatment of chronic pain, including:
~ Headache disorders
~ Autoimmune diseases
~ Inflammatory conditions
~ Mitochondrial dysregulation
~ Spinal cord damage
~ Traumatic brain injuries

PPA is a collaboration between Psychedelics Today, REMAP Therapeutics, and Clusterbusters, and it has received generous seed funding from The RiverStyx Foundation. All of the leaders of PPA are either directly or indirectly impacted by chronic pain.”

Check out PPA today!
https://www.psychedelicsandpain.org/about/

The psꪗchꫀdeꪶics program would be overseen by the Louisiana Department of Health (LDH), which would be responsible for f...
03/26/2026

The psꪗchꫀdeꪶics program would be overseen by the Louisiana Department of Health (LDH), which would be responsible for facilitating clinical trials involving substances that hold therapeutic potential. The bill says that eligible participants would include people with opioid use disorders, co-occurring substance use disorders and treatment-resistant neurological or mental health conditions.

Any studies would need to go through the federal Food and Drug Administration (FDA) investigational drug approval process. Researchers would also need to be permitted by the Drug Enforcement Administration (DEA) to conduct trials involving the Schedule I controlled substances.

Patients participating in the studies would need to go through mental and physical health screening, and researchers would also be required to develop processes that ensure safety and compliance, with adverse event reporting rules, training and licensing for therapists and policies for tracking and handling the psꪗchꫀdeꪶics.



Check out the full article here:
https://www.marijuanamoment.net/louisiana-senators-approve-bill-to-create-psychedelic-therapy-pilot-program-funded-by-opioid-settlement-dollars/

Amid a burgeoning mental health crisis among the nation’s veterans, federal lawmakers and prominent psꪗchꫀdeꪶic advocate...
03/25/2026

Amid a burgeoning mental health crisis among the nation’s veterans, federal lawmakers and prominent psꪗchꫀdeꪶic advocates alike are escalating a bipartisan push to integrate emerging, once-taboo treatments into the country’s largest integrated healthcare system.

The introduction of the new bill marks a significant escalation in the ongoing bipartisan effort to both reshape veteran mental healthcare and expand research into the therapeutic benefits of psꪗchꫀdeꪶics. However, integrating these complex treatments into the sprawling Veterans Health Administration requires navigating a labyrinth of clinical, regulatory, and infrastructural hurdles. 



Check out the full article:
https://www.lucid.news/new-federal-bill-aims-to-establish-va-office-of-novel-therapeutics/

Journalist: .gorsline
News outlet:

The trial will be able to go forward if Huntsman receives funding through legislative appropriations and donations that ...
03/23/2026

The trial will be able to go forward if Huntsman receives funding through legislative appropriations and donations that match or exceed the amount required for the study. Results from the trail will need to be reported to the legislature’s Health and Human Services Interim Committee.

Participants in the study will need to receive the psꪗchꫀdeꪶic treatment in a controlled clinical setting with a qualified therapist who can deliver “trauma-informed preparatory and integrative psychotherapy to the individual before and after administration of the psꪗchꫀdeꪶic drug,” the text of the bill, HB 390, says.

Under the new law signed by the governor, the study is expected to begin by January 1, 2027. However, the Huntsman Institute can continue to accept donations after that point if they are unable to reach the funding goal in time.



Check out the full article here:
https://www.marijuanamoment.net/utah-governor-signs-bill-to-support-clinical-trials-on-psychedelics-for-veterans-mental-health/

The legislation marks a significant step in Mississippi’s exploration of alternative treatments for mental health and ad...
03/20/2026

The legislation marks a significant step in Mississippi’s exploration of alternative treatments for mental health and addiction.

Bryan Hubbard, executive director of Americans for I᥇oᧁainꫀ, has lobbied across states to promote research funding. Hubbard also led a Kentucky opioid settlement effort that aimed to direct millions toward i᥇oᧁainꫀ research.

Supporters cite a 2024 Stanford study suggesting i᥇oᧁainꫀ may reduce symptoms of traumatic brain injury and mental disorders, especially when combined with magnesium.



Check out the full article:
https://desotocountynews.com/mississippi-news/mississippi-governor-signs-law-to-fund-ibogaine-mental-health-trials/

Address

415 S Beretania St
Honolulu, HI
96813

Website

Alerts

Be the first to know and let us send you an email when Nevada Coalition for Psychedelic Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Nevada Coalition for Psychedelic Medicines:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram